Podcasts about cme

Koreen Pagano is a globally recognized expert in skills strategy, AI transformation, analytics, learning technology, and immersive experiences. She founded Tandem Learning, where she pioneered immersive learning through virtual worlds, games, and simulations. She has held product leadership roles at Lynda.com, LinkedIn, D2L, Degreed, and Wiley. Today, Pagano advises organizations on AI and skills transformation in her role as co-founder of Rising Tide Cooperative and CEO of Talent Rewire. She is a seasoned international speaker and author of Immersive Learning and Building the Skills-Based Organization. She lives in Carpinteria, CA.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

"I'd already finished my cardiovascular unit. I'd finished my pulmonary unit. I had never heard about this in any of my classes." That was Dr. Joel Bervell's reaction to discovering that a device used every day in hospitals -- the pulse oximeter -- reads less accurately on darker skin tones. He posted a 30-second video about this consequential discrepancy that, to his utter surprise, gained over 500,000 views by the next morning. That video launched Dr. Bervell into orbit as a social media presence and created his identity as The Medical Mythbuster. In just a few years, he's built a following of two million people, earned a Peabody Award and was named to the inaugural Time 100 Creators list, all while finishing his residency.  On this episode of Raise the Line, host Lindsey Smith welcomes Dr. Bervell to explore the roots of this kind of bias and the real world impact of drawing attention to it. “The most impactful biases in medicine exist because no one stops to ask who was included in the original data and who was left out,” Dr. Bervell explains. Stay tuned to also learn about: His YouTube animated series The Doctor is In which helps kids understand how their bodies work, as well as providing medical role models; How to build trust with marginalized communities; His forthcoming book, The Default Body which examines who medicine was actually designed for. Mentioned in this episode:Dr. Bervell on InstagramTikTok ChannelFacebook"The Doctor Is In" Show If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Today we are doing something we have never done before.Once a month, members of The Metabolic Initiative get an hour to put their own questions directly to the scientists and clinicians at the forefront of metabolic health. Those sessions stay inside the platform. This one does not.After Dr. Ben Bikman joined us for episode 100, the questions kept coming. So we invited him back to sit with Dr. Dominic D'Agostino and MHI co-founder Victoria Field for a live member Q&A, and for the first time we are releasing the full session publicly.What came out of it: GLP-1 medications and the muscle loss debate, and how Ben's own position on these drugs has shifted. Insulin resistance and ceramides. Exogenous ketones, and when they may actually be useful. Metabolic approaches to cancer and the glucose ketone index. Exercise timing. Type 1 diabetes. Cortisol and fat distribution. Supplements.Questions Answered in This Episode:The muscle loss debate around GLP-1s has become polarized. Should clinicians be worried about muscle loss, muscle function, or neither?If you were diagnosed with cancer, are there any metabolic therapies you would start immediately?How long can it take for ceramides in adipose tissue to resolve — and insulin resistance to improve?Bioidentical D-BHB exogenous ketones are substantially more expensive. What is the value proposition over other forms?GLP-1 receptor agonists consistently raise resting heart rate. Is that something to be concerned about?Are there any emerging approaches to improving the management of type 1 diabetes?What happens metabolically, and to fat cells, glucose and ketones, when taking corticosteroids?This is the kind of conversation we host every month inside The Metabolic Initiative, alongside expert presentations from our conferences and a library built entirely around metabolic health and therapy, with CME credit available on eligible content for healthcare providers.If you want to be in the room for the next one, the first seven days are free. membership.metabolicinitiative.comSpecial thanks to the sponsors of this episode:Genova Connect: Get 15% off any Genova Connect test kit with code METABOLICLINK here.Cowboy Colostrum: Get up to 25% off with code METABOLIC here.More LinksDr. Ben Bikman's website: benbikman.comInsulin IQ: insuliniq.comYouTube: youtube.com/@benbikmanInstagram: @benbikmanphdIn every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: InstagramFacebookYouTubeLinkedInPlease keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

In our fourth Summer School episode this season, hosts Dr. Amber Hildreth and Dr. Jordan Whatley have taken highlights from past episodes on liver disease and put them into a special episode full of clinical pearls.Former expert guests Dr. Bill Balistreri, Dr. Jorge Bezerra, Dr. Saul Karpen, Dr. Dennis Black, Dr. Amy Taylor and Dr. Rohit Kohli cover neonatal cholestasis, biliary atresia, PSC, AIH, and MASLD.Our Bowel Sounds Summer School series will include four episodes each summer on big topics in our field, artisanally crafted for the ears of learners of all stages from the young student to the seasoned attending.Learning Objectives:Understand the evaluation of neonatal cholestasisReview the natural history of PSCReview the diagnosis and management of AIHUnderstand the diagnostic evaluation and management of MASLD.Featured episodes:1. Bill Balistreri- Neonatal Cholestasis2. Jorge Bezerra- Advances in Biliary Atresia3. Saul Karpen- Updates in Biliary Atresia4. Dennis Black- Primary Sclerosing Cholangitis5. Amy Taylor- Autoimmune Hepatitis Management6. Rohit Kohli- Fatty Liver DiseaseAdditional Links:1. Guideline for the Evaluation of Cholestatic Infants2. AASLD PSC Guidelines3. AASLD AIH GuidelinesSend us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

What if the conversation in front of you is not asking you to fix anything? As physicians, caregivers, parents, and partners, we are trained to notice suffering and move quickly toward a solution. But even when our intention is to help, fixing can sometimes land as judgment. It can leave the other person feeling unseen, rushed, or as though they need to change. In this episode, Dr. Ni-Cheng Liang and Dr. Jessie Mahoney explore mindful communication as a practice of presence, curiosity, and generosity. They share why listening without immediately advising, correcting, rescuing, or preparing your response can be deeply healing—for the person speaking and for you. Together, they discuss practical ways to arrive more fully before an important conversation: a breath, a hand to heart, a quiet walk, a moment of noticing, or simply an intention to connect. This is not about performing perfect communication. It is an invitation to pause, listen, and remember that sometimes the most healing thing we can offer is our willingness to stay. In This Episode, We Explore Why the instinct to fix can unintentionally communicate judgment The difference between "How can I help?" and deciding what someone needs Listening as a gift of presence, not a tool for solving Why presence and monotasking can conserve emotional energy The question beneath our urge to fix: whose discomfort are we trying to relieve? Simple ways to prepare your body and mind for a difficult conversation How to practice mindful communication with patients, colleagues, children, partners, and parents Reflection Questions When someone comes to you with a problem, is your first instinct to fix or to simply listen? Where might your desire to help sometimes carry an unintended judgment? What does it feel like in your body when you are truly listening? What helps you arrive with presence before an important conversation? Who in your life might benefit from being listened to rather than being fixed? Connect in Nature Retreat Drs. Liang and Mahoney will be offering another Connect in Nature retreat in December, with CME available. Learn more and join them here: www.jessiemahoneymd.com/retreat-connect-in-nature If this conversation resonates, Jessie's coaching offers a place to pause, hear yourself more clearly, and make changes with more presence, self-trust, and ease. 1:1 Coaching: www.jessiemahoneymd.comCME Wellness Retreats: www.jessiemahoneymd.com/retreats Free Live-Stream Mindful Yoga: www.jessiemahoneymd.com/yoga Jessie's Blog: www.jessiemahoneymd.com/jessies-blog Podcast Page: www.jessiemahoneymd.com/mindful-healers-podcast Nothing shared in the Healing Medicine Podcast is medical advice. The Healing Medicine Podcast was formerly known as the Mindful Healers Podcast.  

Brad Stulberg researches, writes, and coaches on performance, well-being, and sustainable excellence. He is the bestselling author of The Practice of Groundedness, Master of Change, and co-author of Peak Performance. Stulberg regularly contributes to the New York Times, and his work has been featured in The Wall Street Journal and The Atlantic among many other outlets. He serves as the co-host of the podcast "excellence, actually" and is on faculty at the University of Michigan. He lives in Asheville, North Carolina.Follow him on Instagram @BradstulbergLink to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Despite gains in recent years, Black, Hispanic, and Asian communities are still under-represented in the U.S. nursing workforce. We're going to explore that gap and how to close it on this episode of Raise the Line from Elsevier with Dr. Ernest Grant, Vice Dean for Diversity, Equity, Inclusion and Belonging at the Duke University School of Nursing. "You get a patient who is more compliant when they see someone who looks like them, who is from their culture and who can advocate on their behalf," he tells host Lindsey Smith.  Dr. Grant bases that and other insights on a rich professional background that includes 50 years in nursing, being a leading advocate for his profession and breaking down barriers himself as a male nurse of color and the first man elected president of the American Nurses Association.  In this thoughtful conversation, Dr. Grant reflects on what it took to earn credibility in leadership roles, how he's navigating the political climate on DEI initiatives, and the causes and solutions to the persistent shortage in nursing faculty, among other pressing issues. Tune in for a uniquely-informed look at what it will take to build a stronger, more representative nursing profession. Mentioned in this episode: Duke University School of Nursing American Nurses Association If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Steve Quirk began his career in 1987 on the fast-paced trading floors of Chicago, surviving the historic market crash that wiped out $1.7 trillion worldwide.From navigating open-outcry pits where a trader's word was their bond, Steve transitioned into market technology, helping build landmark tools at thinkorswim and leading trading strategy initiatives at TD Ameritrade. Today, as Chief Brokerage Officer at Robinhood, he sits at the intersection of retail investing, market structure, and financial innovation, shaping products for millions of retail investors.In this conversation, Steve shares key lessons from decades in the markets, the evolution of retail trading technology, and how removing friction like the Pattern Day Trader rule is unlocking the next era of retail investing. In this episode, we explore:• Steve's early days in the Chicago trading pits in 1987• Why decisive decision-making and accepting being wrong 50% of the time is crucial• The transition from floor trading to building technology at thinkorswim• How Robinhood levels the playing field for retail investors and opens up global access• Managing risks: framing the absolute worst-case scenario before taking a trade• The impact of removing the Pattern Day Trader (PDT) rule for retail traders About Steve Quirk:Steve Quirk is Chief Brokerage Officer at Robinhood Markets. With over 35 years of financial markets experience, he previously led trading strategy at TD Ameritrade, developed innovative trading tools for thinkorswim®, and created the TD Ameritrade U program. Steve started his career in 1987 in the Chicago open-outcry pits across the CME and CBOE, and is a frequent market commentator featured on CNBC, Fox Business, and The Wall Street Journal. Links + Resources:LinkedIn: https://www.linkedin.com/in/steve-quirk-56148a22/X (Twitter): https://x.com/SteveQuirk_ Sponsor of Chat With Traders Podcast:Trade The Pool: http://www.tradethepool.com Time Stamps:Please note: Exact times will vary depending on current ads. 00:00 From Chicago Pit Trader to Robinhood Exec 02:57 What Pulled You to the Market? 07:17 Trading Pits Are More Organized Than They Appear 11:51 Transitioning to Creating Technology for Retail Trading 19:01 Leveling the Playing Field for Retail Traders 21:10 Giving People What They Want 24:45 Did You Fall in Love with Scaling Robinhood Like You Did with Trading? 29:48 What Robinhood Is Doing to Teach 32:12 Early Mistakes in Trading
 34:31 Advice to People from Robinhood CBO
 36:44 What's Your Next Product Going to Be?
 40:24 What Is the PDT Rule?
 43:23 What Is a Memory That Came to Mind in Your Trading Career?
 45:16 Is There Anything in Your Life That Changed Your Line of Thinking?
 46:22 Your Piece of Advice to Your Younger Self 46:57 Where Can Traders Find You? Trading Disclaimer: Trading in the financial markets involves a risk of loss. Podcast episodes and other content produced by Chat With Traders are for informational or educational purposes only and do not constitute trading or investment recommendations or advice. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode explores complex questions around addiction treatment from our audience, including the off-label use of GLPs for SUDs, the nuances of naloxone, and managing high-dose methadone in hospital settings. Experts Drs. Shawn Cohen and Zina Huxley-Reicher, in addition to the co-hosts Drs. Carolyn Chan and Era Kryzhanovskaya share insights, resources, and practical tips for clinicians navigating these challenging scenarios.Claim CME for this episode at curbsiders.vcuhealth.org!By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education.Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME!Show Segments Intro, disclaimer Picks of the Week Off-Label GLP use Naloxone review Acute pain in patients with opioid use disorder (OUD) Care Coordination with opioid treatment programs (OTPs) New medications for pain; suzetrigine Perioperative pain management for patients with OUD Outro Credits Producer, Show Notes, Infographic: Era Kryzhanovskaya, MD Hosts: Carolyn Chan, MD. MHS and Era Kryzhanovskaya, MD Reviewer: Kenny Morford, MD Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Shawn Cohen, MD; Zina Huxley-Reicher, MD Sponsor: The Permanente Medical GroupJoin us in New York City as we host Information Sessions on Thursday, August 20th, Friday the 21st, and Saturday the 22nd, , as well as a Social Mixer at the Castell Rooftop Lounge on Friday, August 21st. Visit northerncalifornia.permanente.org and RSVP todaySponsor: UpToDateFor a limited time, listeners can get 10% off UpToDate packages with code CURB1. Visit store.uptodate.com.Sponsor: FIGSGet 15% OFF your first order at wearfigs.com with code FIGSRX.Sponsor: Quince Download the Quince app for app-exclusive offers, or go to Quince.com/curb. Get free shipping on your order and 365-day returns

Highlights from the PER® CME activity "Key Considerations for Health Equity and Patient-Centered Care in TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts Aditya Bardia, MD, MPH, FASCO, and Kathryn E. Post, PhD, ANP-BC, discuss key drivers of disparities in outcomes for triple-negative breast cancer and strategies for patient-centered communication, from shared decision-making to managing treatment-related toxicity.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/key-considerations-for-health-equity-and-patient-centered-care-in-tnbcThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Read out and read – How Stories Build Stronger Families How can a simple book help shape a child's brain, strengthen family relationships, and promote lifelong learning? In this episode of the Medical College of Georgia Pediatric Podcast, medical student Megan Garrison, pediatric resident Jessie Foglio, and pediatrician Dr. Erica Sapp explore the powerful impact of Reach Out and Read. Learn how shared reading during early childhood supports language development, strengthens caregiver-child bonds, promotes health equity, and gives pediatric healthcare professionals a unique opportunity to support families—one book at a time. CME available free with sign up: Link coming soon!

Ethereum is one of the largest digital assets in the world—but if you believe in its long-term potential, what's actually the best way to trade or invest in it? That's a great viewer question, and the answer isn't nearly as simple as just saying, "Buy ETH." In today's episode, we'll start with the basics: What exactly is Ethereum, what does Ether (ETH) do, and why does the network have value? Ethereum isn't simply a cryptocurrency. It's a programmable blockchain designed to run smart contracts and decentralized applications, creating infrastructure for everything from stablecoins and DeFi to tokenization and other digital assets. (ethereum.org) Then we'll get to the bigger question: If you want exposure to Ethereum, what's the BEST way to do it? We'll break down the major choices available to traders and investors: Buy ETH directly – Own the actual cryptocurrency and decide whether to hold it on an exchange or in your own wallet. Buy and stake ETH – Hold the asset while participating in Ethereum's proof-of-stake ecosystem and potentially earning staking rewards. (ethereum.org) Ethereum ETFs – Get ETH exposure directly inside a traditional brokerage or retirement account without dealing with wallets and private keys. Staking Ethereum ETFs – A newer twist that may allow investors to combine ETH price exposure with staking income. SEC filings now include products specifically structured around Ethereum staking. (sec.gov) Ethereum futures – For active traders looking for leverage, short exposure, hedging, and nearly around-the-clock access through regulated futures markets. (cmegroup.com) Micro Ether futures – A much smaller contract that can make position sizing and risk management considerably easier. CME's Micro Ether futures represent just 0.10 ETH. (cmegroup.com) Ethereum options – For traders looking to build more sophisticated strategies around volatility, direction, income, and risk. And here's where it gets interesting... There may not actually be one "best" way to trade Ethereum. The best vehicle depends on what you're trying to accomplish. Are you a long-term investor? An active trader? Do you want leverage? Do you want staking yield? Do you want self-custody? Do you want ETH exposure inside an IRA? Or do you simply want to speculate on whether Ethereum goes up or down? Before deciding whether Ethereum is a good investment, you need to understand both the asset AND the vehicle you're using to trade it. We'll compare the advantages, disadvantages, costs, risks, custody considerations, leverage, and potential staking income associated with each approach. And, of course, we'll discuss the bigger picture: What gives Ethereum value in the first place—and what could drive ETH higher or lower from here? For additional research, check out the official Ethereum website and CME Group's Ether Futures & Options. Listen now:

Lavon Medlock has spent over two decades enhancing leaders' skills in problem-solving and coaching. Skilled in a variety of continuous improvement methods, she has trained leaders in creating effective daily management systems, deployed an integrated facility design approach to new construction projects like a 90,000-square-foot patient tower, and enhanced operations across different sectors.With a primary focus on the healthcare industry, Lavon has worked with clinical leaders to combine the Institute of Healthcare Improvement's teachings on quality with A3 thinking and key project management principles. She's a practitioner, teacher, and coach in the field of A3 thinking and holds certifications in both Project Management (PMI-PMP) and Six Sigma Green Belt.In addition to instructing and coaching for the Lean Enterprise Institute, she teaches graduate coursework at The Ohio State University. Her educational background includes a Bachelor of Science in Public Health from the University of North Carolina at Chapel Hill and a Master of Science in Healthcare Administration from Oregon Health & Science University.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

What does it take to compete on the world's biggest stage and then pivot to one of the most demanding training paths in professional life? Today's guest, Samantha "Sammy" Kolowrat, has done both, and she has some fascinating insights into the commonalities of those two worlds on this episode of Raise the Line. “Something that really drew me to medicine is the team atmosphere that's there as you work towards a common goal, and there's this level of intensity that's very reminiscent of the experiences I had as a professional athlete.” Originally from Prague, Kolowrat represented Czechia at six IIHF Women's World Championships and the 2022 Beijing Olympics, and also captained the Division I women's hockey team at the University of Vermont while earning degrees in biology and pharmacology.  As she starts an anesthesiology residency at Vanderbilt University, she credits her athletic career with shaping how she handles pressure, feedback, and teamwork in medicine. "The more I improve, the more knowledge I acquire, the more skills I hone, the better care my patients get," she tells host Lindsey Smith, describing what drew her to a field that rewards the same relentless fine-tuning as elite sports. This engaging conversation also explores: How crippling performance anxiety as a Division I athlete ended up preparing Kolowrat for the operating room; Why she was drawn to anesthesiology's "well-oiled machine" atmosphere; The mentorship gap she's working to close for the next generation of athlete-physicians. Mentioned in this episode: Vanderbilt University Anesthesiology Residency Program If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

From Sonographer to App Founder: Lynn Flam Builds SonoTechniques AcademyNick Holdinghausen and his co-host introduce Southern Illinois Now's Small Town Big Business and interview Lynn Flam, a registered diagnostic medical sonographer with 34 years of OBGYN experience who launched the SonoTechniques Academy OBGYN ultrasound teaching app and The Seasoned Sonographer podcast after career burnout and a lack of local teaching jobs. Flam describes identifying an education gap as busy OBGYN offices struggle to take students, using SBDC Carbondale resources to plan and find developer Jeremy Packer (Packer Labs), and marketing primarily through social media, including TikTok, plus costly conferences. The app is used by SIU's program and a local hospital system as a reference for protocols and checklists. She also became a CME lecturer, presenting on ectopic pregnancies and first-trimester evaluation, and discusses AI's growing role in ultrasound.Recorded at EThOs Small Business Incubator and Co-working Spaces in Marion, Illinois.https://members.ethosmarion.org/ SUBSCRIBE TO THE PODCASTOur guest: https://sonotechniquesacademy.com/

Learn how AI, 3D imaging, and expert-led education are transforming maternal-fetal medicine. Discover what's new in diagnosing fetal malformations, placental disorders, and complicated twin pregnancies - plus the latest on O-RADS and hybrid CME opportunities. World Class CME City: Charlotte Address: 6201 Fairview Rd. Website: https://worldclasscme.com/

Featuring perspectives from Dr Wassim Abida, Dr Rahul Aggarwal, Dr Emmanuel S Antonarakis, Prof Karim Fizazi and Dr Rana R McKay, moderated by Dr McKay, including the following topics: Introduction (0:00) Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Antonarakis (2:42) Current and Future Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Aggarwal (26:23) Current and Future Role of Regimens Combining PARP Inhibitors and Androgen Receptor (AR) Pathway Inhibitors in Metastatic Prostate Cancer — Dr Abida (53:01) Emerging Role of AKT Inhibition for Patients with mHSPC — Prof Fizazi (1:17:22) Current and Future Use of Radiopharmaceuticals in Metastatic Prostate Cancer — Dr McKay (1:39:37) CME information and select publications

Obstructive sleep apnea affects approximately one in four adults and is especially common among patients with neurologic disorders, including stroke, Parkinson disease, dementia, epilepsy, and neuromuscular conditions. In this episode, Dr. Stephanie Stahl discusses why neurologists should routinely screen for OSA, highlights key symptoms and risk factors, reviews important considerations when interpreting sleep studies, and outlines current treatment options beyond CPAP. Learn how recognizing and treating sleep apnea can improve quality of life, optimize management of neurologic disease, and reduce long-term health risks. In this episode, Aaron L. Berkowitz, MD, PhD, FAAN, speaks with Stephanie M. Stahl, MD, FAASM, author of the article "Obstructive Sleep Apnea" in the Continuum® August 2026 Sleep Neurology issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Dr. Stahl is an Associate Professor of Clinical Medicine and Sleep Medicine Fellowship Program Director at Indiana University School of Medicine in Indianapolis, Indiana, where she also serves as Sleep Laboratory Medical Director in the Division of Pulmonary, Critical Care, Sleep, and Occupational Medicine. Additional Resources Read the article: Obstructive Sleep Apnea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz  Full episode transcript available here Dr Berkowitz: Obstructive sleep apnea is very common. It can cause or contribute to common neurologic symptoms, such as headache and impaired cognition, and it's a risk factor for stroke. And yet, if you're like me, you may not know too much more about sleep apnea than that. Today, I have the pleasure of talking to sleep expert Dr. Stephanie Stahl to learn what every neurologist should know about OSA.  Dr Jones:  This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Berkowitz: This is Dr. Aaron Berkowitz. Today I'm interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the 2026 Continuum issue on Neurology of Sleep. Welcome to the podcast, Dr. Stahl, and could you please introduce yourself to our audience?  Dr Stahl: Yeah. Thank you for having me. I'm a sleep medicine physician and neurologist and medical director of the Indianapolis Sleep Lab at Indiana University Health. I serve as the director of the Sleep Medicine Fellowship program. I'm faculty advisor for our very first student interest group in sleep medicine at Indiana University School of Medicine. I'm also actively involved in some national leadership roles, including the incoming chair of the American Academy of Sleep Medicine's Education Committee and co-chair of the Academy's Inter-Scorer Reliability Gold Standard Panel. So, I really appreciate this opportunity. I look forward to our discussion.  Dr Berkowitz: Me too, and we appreciate the opportunity too to get to talk to you. You have so much expertise in this area, and I certainly encourage our listeners to look at your article, which is very comprehensive and up to date, and I learned a ton from it. I didn't get much exposure to sleep neurology as a trainee, and I've always worked in academic centers where we have a sleep group and we can refer patients there. So, I have to admit, sleep may probably be the area of neurology I know the least about, and felt like I was learning something new from pretty much every line of your article, and I know our readers will too. So, your article has a lot of excellent detail for our readers on the diagnosis and treatment of this very common condition. But I'd like to keep our interview relatively high level today and focus on the essentials for the practicing general neurologist. So, to start, can you just give us a sense of what obstructive sleep apnea is, and what every neurologist should know about it?  Dr Stahl: Yeah. So obstructive sleep apnea is characterized by either partial or full obstructions in the upper airway. That may sound pretty simple, but this leads to a whole bunch of issues. It leads to oxygen desaturations, arousals from sleep, leading to sleep fragmentation. This can then lead to sympathetic nervous system activation, cerebral hypoperfusion, leading to a whole bunch of symptoms or neurologic conditions.  Dr Berkowitz: Great. And you mentioned this in your article, but just to emphasize, how common is obstructive sleep apnea in the general population?  Dr Stahl: Yeah. So, about a quarter of the general population have obstructive sleep apnea. Much more common in many neurologic conditions.  Dr Berkowitz: Yeah, so very common disorder. We are seeing patients with it quite frequently, whether that's the reason they are seeing us in neurology or not. And this leads to my next question, which is what neurologic symptoms or presenting concerns of a patient should make us think about OSA and the differential diagnosis, and what factors based on the history or the exam or the context would make you suspicious for OSA as the cause of a neurologic symptom? In other words, the patient's presenting with classic symptoms of OSA, and that's why they're seeing a neurologist or seeing a primary care doctor, but is coming for evaluation of, say, headache or other symptoms. And what symptoms would make you think of wanting to consider OSA, and then what aspects of the history or otherwise would make you want to evaluate the patient for OSA?  Dr Stahl: I think a really important takeaway is for neurologists to know that obstructive sleep apnea is very common in neurologic conditions and has that potential to worsen a lot of these conditions or their associated symptoms. And so, it should be on our radar. There are certainly some basic questions and signs and symptoms that we can ask patients about or, or take a look at on exam. And so particular symptoms include snoring. Anybody that snores loudly or frequently, that's a strong risk factor for obstructive sleep apnea. If someone's seeing them stop breathing in their sleep, if they are waking up a lot throughout the night. There are some other symptoms that we may not necessarily attribute upfront to obstructive sleep apnea, such as nocturia, nocturnal reflux, night sweats. There are some daytime symptoms, of course, too, like unrefreshing sleep, daytime sleepiness, morning headaches, an important one in neurology. And then we take a look at the patient's exam. And so, some things that neurologists might want to be thinking about are people with obesity are certainly at a risk for obstructive sleep apnea. But it's also very important to know that someone does not need to have obesity in order to have obstructive sleep apnea. We look at neck size, other morphologic characteristics, such as how much that we can see in the back of their mouth. Can we see their uvula? Does their tongue size appear large in their mouth? And then some other risk factors too, such as male gender, older age, family history, post-menopausal state in women. All that being said, though, sometimes in neurologic conditions, we don't have all of those symptoms or risk factors to be thinking about. And so, in certain neurologic conditions such as stroke where obstructive sleep apnea is very common and has the potential to increase the risk of another stroke, we may need to be thinking about testing these patients even with minimal symptoms or other risk factors.  Dr Berkowitz: That's very helpful. So, you mentioned their headache might be the presenting symptom, right, to a neurologist, and we should certainly be thinking about obstructive sleep apnea as a potential diagnosis, even the cause of the patient's headache, particularly you said patients with morning headache. I often try to think about in patients presenting with, for memory loss, or other cognitive concerns, and that may be due more to inattention from poor sleep, so asking about sleep and symptoms of sleep apnea in those contexts. Are there any other presenting neurologic symptoms not particularly related to sleep? I'm thinking of headache, memory loss, other symptoms that would make you think, "Oh, I should actually screen this patient for sleep apnea also."  Dr Stahl: Yeah, other symptoms to think about in pediatrics, hyperactivity, people that have impaired vigilance, as you alluded to, that poor attention. Sometimes people get misdiagnosed with ADHD, and it's actually just a manifestation of obstructive sleep apnea.  Dr Berkowitz: You alluded to this, Dr. Stahl, that stroke, for example, patients are at higher risk of developing sleep apnea as a result of stroke, and it's also a risk factor for stroke. What other neurologic conditions, primary neurologic diseases, put patients at a higher risk of OSA? And again, similar to the last question I asked you, what are some clues that we should evaluate for? We might be following a patient for their post-stroke care over time and not necessarily thinking about diagnosing a separate condition in them since we're following them for their stroke or their degenerative disease. What are the conditions that put patients at a higher risk of OSA as a result of the condition, and then when would you think about screening them for it?  Dr Stahl: Some particular neurologic conditions where obstructive sleep apnea are very common, in addition to stroke and, and TIA, include Parkinson disease. It can worsen a lot of the motor, cognitive symptoms, sleep disruption that we can see in Parkinson disease. Very common in all causes of dementia, but in particular Alzheimer disease and Lewy body dementia. Very common in neuromuscular conditions. We should definitely have obstructive sleep apnea and all forms of sleep-disordered breathing high on our radar. In conditions like myotonic dystrophy. Charcot-Marie-Tooth is another one where obstructive sleep apnea is very common. Myasthenia gravis, it can worsen the symptoms of that. In particular, a pearl is if somebody has morning weakness in myasthenia gravis, obstructive sleep apnea should be high on your radar. And also, as you mentioned, any forms of headaches. There are some other things too. If somebody has poor seizure control, especially nocturnal seizures, you might have obstructive sleep apnea on your radar as well.  Dr Berkowitz: So, I think you've covered essentially every category of neurologic disease, right? We have cerebrovascular, movement, neurodegenerative, neuromuscular, epilepsy, all conditions where either the disorder itself, such as stroke or the, correct me if I'm wrong, the neurodegenerative disease puts the patient at risk. Or the patient may be at risk for exacerbations of their disease, as you mentioned in myasthenia. I love that pearl. Not fatiguable at the end of the day, but if the patient with myasthenia is telling you they're feeling weaker at the beginning of the day, then think about obstructive sleep apnea and that obstructive sleep apnea worsening control of epilepsy due to poor sleep. So really a lot of bidirectional interactions with this common condition. Okay, so if we're concerned about obstructive sleep apnea, again, myself, a general neurologist speaking perhaps on behalf of other general neurologists, we see a patient with headache or reporting memory loss that we find to be impaired attention, or we see exacerbation of their underlying primary neurologic disease. As you mentioned, we think, "Oh, I've listened to this podcast. I've read Dr. Stahl's article. I should probably be thinking about OSA in this patient, and I should order a sleep study." Now, I admit when I get the sleep study back, I scroll to the bottom, I see they do have obstructive sleep apnea, I'm going to send them over to a sleep specialist. But for the general neurologist, what are some high-yield pearls and some pitfalls to be aware of when we get sleep studies for obstructive sleep apnea, and we are looking at the results? Dr Stahl: The first thing is to understand that there are two main types of sleep studies: in-lab polysomnography and home sleep apnea test. In-lab studies are typically what we consider the more accurate type of study. Main reason for that is that we have EEG, so we can see if someone is awake versus asleep. Most home sleep apnea tests do not utilize EEG, and so when we're looking at respiratory events, apneas or hypopneas, we're looking at over the total recording time rather than the total sleep time. So, we know we're going to capture some time where a person is awake, where we don't have sleep apnea events, and that can be a big amount of time in people with insomnia, poor sleep efficiency. And as a result of that, it can lead to an underestimation of the apnea-hypopnea index. That's really important for people to understand that that means we can end up with a false negative home sleep apnea test, or it can put them in a category of lower severity than what they actually have. And so, if you get a home sleep study report back that's negative for sleep apnea and you remain concerned, you need to go on to do an in-lab study, where about twenty to fifty percent of people will go on to have a positive in-lab study. You can also get false positives with home sleep apnea tests too, and so ideally, we should only be doing home sleep apnea tests in people that are at high risk of having obstructive sleep apnea to decrease our chance of false positive study. When we get that sleep study report, what's important to take a look at? So the main number that we look at currently is the apnea-hypopnea index. The number of apneas, which are full obstructions in that upper airway, or hypopneas, partial obstructions in the upper airway where either there's an oxygen desaturation or an arousal associated with that. Less than five is considered to be normal. Anything five or more gives them a diagnosis of obstructive sleep apnea, and then we stratify them based on the AHI. But it's important to take a look at more than just the apnea-hypopnea index. And while my eyes too on various reports like echocardiograms want to jump to the impression, it is important to take a look at that full report, see what their oxygen levels averaged and what they dipped down to. The arousal index, which is how many times a patient may have woken up briefly throughout the night. Take a look at the histogram, usually an image at the bottom of their report that shows what sleep fragmentation may have been like so that you can take that all in and make that decision. How important are these study findings, and is this a person that would benefit from treatment?  Dr Berkowitz: That's a fantastic overview of sleep studies and some of the highlights to look out for, even if we won't be understanding every detail as you would to know most importantly the caveats about home sleep testing having a fairly high percentage of false negative and false positive results. So being wary if our suspicion is high, and that test is normal or inconclusive to get an in-lab sleep study. And if our suspicion is low or maybe we haven't ordered the test and the patient has had it done elsewhere, and the history doesn't really match up to know that there are false positives on the home studies as well, and again, an in-lab study to settle the diagnosis. Is that right?  Dr Stahl: Yes.  Dr Berkowitz: Okay. Now, for most neurologists, probably if we diagnose OSA, we will be referring the patient to a sleep specialist like yourself for treatment. I think we're all familiar with CPAP and patients being on CPAP. Your article mentions a number of treatment modalities I admit I have not heard of before or maybe heard of in passing, acknowledging most general neurologists are not going to be prescribing or knowing with the nuance that you do as an expert how to decide which treatment a patient would most benefit from or most qualify for. So, can you just give us a broad overview, again, for the general neurologist acknowledging we might see a patient whose past medical history says OSA being treated with fill in the blank. What are the different treatment modalities, and how do you think, just so we can learn from you in broad brush strokes, about particular treatments for particular patients?  Dr Stahl: As you mentioned, most people are familiar with positive airway pressure or PAP therapy, and that does remain our most efficacious treatment. The way I explain it to patients is why PAP therapy is the most effective treatment is it's the only treatment that can take all of the tissues of that upper airway and open them up. Whereas all of our other treatments, we're going to target smaller spaces of that upper airway. So, our first option is if we can get somebody on PAP therapy, we know that that's going to be the best option for the majority. PAP therapy works by basically acting as an air splint to open up the air tissues. Know that masks are not interchangeable. There are masks that cover the nose and go over the nose and mouth and under the nose. Full face masks that cover the nose and mouth, they do typically require higher pressures, also tend to be less comfortable for a lot of patients as well. In addition to different PAP masks, there's different modalities of positive airway pressure therapy too. There are machines that auto-adjust, some that provide fixed pressure, bi-level PAP that provides a higher inspiratory pressure, lower expiratory pressure. Then outside of PAP therapy, there are, as you alluded to, a lot of options and more, continuing to come down the pipeline as well. Mandibular advancement devices or a form of oral appliances has been around for a while. This is device that somebody wears in their mouth. It's preferably customized for their teeth and titratable, meaning that they can make adjustments that pulls their mandible forward in relation to the maxilla in order to pull those tongue tissues further away from the back of the upper airway. That's ideally managed by a qualified sleep dentist or someone that specializes in oral appliance management. Other treatments include surgical options, including hypoglossal nerve stimulation, which is an implanted device that causes the tongue to protrude repetitively throughout their sleep period to hopefully open up the airspace. There's some other surgical options too that open up various places of the upper airway. There's a daytime treatment of obstructive sleep apnea, transoral neuromuscular electrical stimulation that changes the muscle fiber type of the tongue. And then there's some adjunctive treatments that can be helpful too, such as positional therapy, oral facial myofunctional therapy that helps a person breathe better through their nose and may help train the upper airway muscles.  Dr Berkowitz: Great. Well, that's a very helpful overview, and again, I refer our listeners to your article, which talks about all of those modalities in very comprehensive detail. So, Dr. Stahl, as we wrap up our conversation, you have a captive audience of neurologists and neurology trainees here. What would you like to leave us with that every neurologist should know about obstructive sleep apnea?  Dr Stahl: The most important, again, is for neurologists to know that obstructive sleep apnea is so common in your patient population, and it can have a significant negative impact on quality of life and health, including many neurologic conditions. And at the same time, obstructive sleep apnea is very treatable. We have so many options nowadays that we can usually get someone onto adequate treatment. And treatment has that potential to improve several neurologic symptoms and disorders, even at times when you don't think that there's an opportunity to improve symptoms such as say in, headache. So, neurologists really should be screening for signs and symptoms of obstructive sleep apnea, as well as considering testing in high-risk, potentially asymptomatic or minimally symptomatic patients.  Dr Berkowitz: That's a fantastic overview of some of the many pearls that you shared with us today, as well as in your article. So, thank you so much again. Today, I've been interviewing Dr. Stephanie Stahl about her article on obstructive sleep apnea. This article appears in the August 2026 Continuum issue on neurology of sleep. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining today, and thank you again, Dr. Stahl.  Dr Stahl: Thank you again for having me.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.  

AUA2026: Focus on: Non-Muscle Invasive Bladder Cancer Update for the Urology Care Team CME Available: https://cme.auanet.org/URL/FOCUS263ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Analyze emerging data in NMIBC and guideline updates to evaluate the impact of disease recurrence and treatment-related complications on current care pathways and patient outcomes. 2. Apply guideline-driven risk stratification in order to identify and select appropriate patients with high-risk NMIBC for optimal therapy sequencing and escalation of care. 3. Implement strategies for safe and effective integration of novel intravesical and systemic immunotherapies to strengthen multidisciplinary collaboration and shared decision-making between urology and medical oncology. 4. Develop patient-centered, evidence-informed care plans using guideline updates and real-world case examples, in order to address unmet needs, reduce recurrence risk, and improve quality of life for patients with NMIBC. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca ImmunityBio Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC UroGen Pharma, Inc.

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode we discuss:Higher dietary intake of B vitamins B3 and B12 is associated with a lower risk of developing glaucoma.Prior vitrectomy may come with postoperative baggage, with a nearly 4-fold higher risk of CME after cataract surgery.Ocular herpes doesn't affect cancer risk, except in patients with underlying immune dysfunction.A little overcorrection after intermittent exotropia surgery hits the sweet spot for long-term alignment.Senescent “zombie” cells stick around and fuel the tissue damage that causes keratoconus.

✔️ Bitcoin has broken out of the linear falling wedge ✔️ We're about to have our first cycle that's aligned with the business cycle in 6 years✔️ Hedge funds on CME flipped net long BTC futures✔️ Larger players have been steadily accumulating.✔️ The Bitcoin Power Law model suggests BTC should be ~$175,000 today✔️ Bitcoin has bottomed against the US stock market.✔️ BTCPayserver donating to sparrow wallet & the RED team✔️ BPI Publishing open letter to worlds leading AI labs✔️ Notice of ICANN .bitcoin TLD community application✔️ Clarity Act Update ✔️ BIP-110 ✔️ Blast from the past ✔️ Sources:► https://x.com/superbitcoinbro/status/2086944121273672120► https://x.com/philc411/status/2086948347907080350► https://x.com/RonSwanonson/status/2086667570367836196► https://x.com/philc411/status/2086960864834244943► https://x.com/ki_young_ju/status/2086684024173727783► https://x.com/killaxbt/status/2086800481704403222► https://x.com/philc411/status/2087197685912571987► https://x.com/IIICapital/status/2087181176146428369► https://x.com/gordongekko/status/2087194199376404584► https://x.com/btcpayserver/status/2086875600103367109► https://x.com/bitcoinpolicy/status/2086872430639771675► https://x.com/alexbosworth/status/2086836074115109201► https://x.com/wiz/status/2085029140453830725► https://x.com/wiz/status/2087148145105080750► https://x.com/theblockco/status/2087025939389845758► https://x.com/pete_rizzo_/status/208726719962275856► https://x.com/watcherguru/status/2087232342905536833► https://www.paulhastings.com/insights/crypto-policy-tracker/cloture-filed-on-clarity-act-motion-to-proceed-cftc-to-advance-crypto-rules-either-way-fdic-approves-digital-asset-bank-and-court-rules-for-utah-on-event-contracts► https://x.com/peterktodd/status/2087194653019746734► https://x.com/mrhodl/status/2087181358468567052► https://x.com/mononautical/status/2087182951721402445► https://x.com/darosior/status/2087185233346986168► https://x.com/stutxo/status/2087300136934264992► https://x.com/grassfedbitcoin/status/2087251876442251683► https://x.com/gmoneypepe/status/1866684816542032323► DONATE TO HELP KEONNE AND BILL https://www.change.org/p/stand-up-for-freedom-pardon-the-innocent-coders-jailed-for-building-privacy-tools✔️ Check out Our Bitcoin Only Sponsors!► https://archemp.co/Discover the pinnacle of precision engineering. Our very first product, the bitcoin logo wall clock, is meticulously machined in Maine from a solid block of aerospace-grade aluminum, ensuring unparalleled durability and performance. We don't compromise on quality – no castings, just solid, high-grade material. Our state-of-the-art CNC machining center achieves tolerances of 1/1000th of an inch, guaranteeing a perfect fit and finish every time. Invest in a product built to last, with the exacting standards you deserve.► Join Our telegram: https://t.me/theplebunderground#Bitcoin #crypto #cryptocurrency #dailybitcoinnews #memecoinsThe information provided by Pleb Underground ("we," "us," or "our") on Youtube.com (the "Site") our show is for general informational purposes only. All information on the show is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information on the Site. UNDER NO CIRCUMSTANCE SHALL WE HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE SHOW OR RELIANCE ON ANY INFORMATION PROVIDED ON THE SHOW. YOUR USE OF THE SHOW AND YOUR RELIANCE ON ANY INFORMATION ON THE SHOW IS SOLELY AT YOUR OWN RISK.

✔️ Bitcoin has broken out of the linear falling wedge ✔️ We're about to have our first cycle that's aligned with the business cycle in 6 years✔️ Hedge funds on CME flipped net long BTC futures✔️ Larger players have been steadily accumulating.✔️ The Bitcoin Power Law model suggests BTC should be ~$175,000 today✔️ Bitcoin has bottomed against the US stock market.✔️ BTCPayserver donating to sparrow wallet & the RED team✔️ BPI Publishing open letter to worlds leading AI labs✔️ Notice of ICANN .bitcoin TLD community application✔️ Clarity Act Update ✔️ BIP-110 ✔️ Blast from the past ✔️ Sources:► https://x.com/superbitcoinbro/status/2086944121273672120► https://x.com/philc411/status/2086948347907080350► https://x.com/RonSwanonson/status/2086667570367836196► https://x.com/philc411/status/2086960864834244943► https://x.com/ki_young_ju/status/2086684024173727783► https://x.com/killaxbt/status/2086800481704403222► https://x.com/philc411/status/2087197685912571987► https://x.com/IIICapital/status/2087181176146428369► https://x.com/gordongekko/status/2087194199376404584► https://x.com/btcpayserver/status/2086875600103367109► https://x.com/bitcoinpolicy/status/2086872430639771675► https://x.com/alexbosworth/status/2086836074115109201► https://x.com/wiz/status/2085029140453830725► https://x.com/wiz/status/2087148145105080750► https://x.com/theblockco/status/2087025939389845758► https://x.com/markartymko/status/2087195673259065796► https://x.com/pete_rizzo_/status/208726719962275856► https://x.com/watcherguru/status/2087232342905536833► https://www.paulhastings.com/insights/crypto-policy-tracker/cloture-filed-on-clarity-act-motion-to-proceed-cftc-to-advance-crypto-rules-either-way-fdic-approves-digital-asset-bank-and-court-rules-for-utah-on-event-contracts► https://x.com/peterktodd/status/2087194653019746734► https://x.com/mrhodl/status/2087181358468567052► https://x.com/mononautical/status/2087182951721402445► https://x.com/darosior/status/2087185233346986168► https://x.com/stutxo/status/2087300136934264992► https://x.com/grassfedbitcoin/status/2087251876442251683► https://x.com/gmoneypepe/status/1866684816542032323► DONATE TO HELP KEONNE AND BILL https://www.change.org/p/stand-up-for-freedom-pardon-the-innocent-coders-jailed-for-building-privacy-tools✔️ Check out Our Bitcoin Only Sponsors!► https://archemp.co/Discover the pinnacle of precision engineering. Our very first product, the bitcoin logo wall clock, is meticulously machined in Maine from a solid block of aerospace-grade aluminum, ensuring unparalleled durability and performance. We don't compromise on quality – no castings, just solid, high-grade material. Our state-of-the-art CNC machining center achieves tolerances of 1/1000th of an inch, guaranteeing a perfect fit and finish every time. Invest in a product built to last, with the exacting standards you deserve.► Join Our telegram: https://t.me/theplebunderground#Bitcoin #crypto #cryptocurrency #dailybitcoinnews #memecoinsThe information provided by Pleb Underground ("we," "us," or "our") on Youtube.com (the "Site") our show is for general informational purposes only. All information on the show is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any information on the Site. UNDER NO CIRCUMSTANCE SHALL WE HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE SHOW OR RELIANCE ON ANY INFORMATION PROVIDED ON THE SHOW. YOUR USE OF THE SHOW AND YOUR RELIANCE ON ANY INFORMATION ON THE SHOW IS SOLELY AT YOUR OWN RISK.

MRKT Matrix - Tuesday, August 11th S&P 500 falls amid Iran uncertainty, Big Tech losses (CNBC) An inflation report Wednesday should be a big deal for the Fed. Here's what to expect (CNBC) Santoli: Stocks return to winning ways. Why the market gods may not be satisfied with July's brief pain (CNBC) One big question remains for the bull market, says Bank of America (CNBC) Investors poured $2.3 billion into this riskier corner of the bond market in July (CNBC) Nvidia is trying to quiet ‘circular financing' accusations. Wall Street is unsure it will (CNBC) AI computing power is becoming a tradable asset class as CME launches futures contracts (CNBC) SpaceX shares can more than double, Morgan Stanley says. The bull thesis isn't based on space business (CNBC) --- Subscribe to our newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://riskreversal.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ MRKT Matrix by RiskReversal Media is a daily AI powered podcast bringing you the top stories moving financial markets Story curation by RiskReversal, scripts by Perplexity Pro, voice by ElevenLabs

Ketogenic and low-carbohydrate diets often focus on a specific carbohydrate target: keep your net carbs under 30 grams. But as registered dietitian and certified diabetes educator Franziska Spritzler demonstrates in this presentation from Metabolic Health Summit, a carbohydrate target is not a therapy. Effective implementation means a full assessment of medical history, medications, labs, food preferences, lifestyle, and the motivation that will carry a patient through year one and beyond.Spritzler specializes in low-carbohydrate and ketogenic nutrition and has extensive experience helping people use these approaches to improve metabolic health. The creator of lowcarbdietitian.com, she walks through the practical decisions clinicians face: when a ketogenic diet is warranted versus a more flexible low-carbohydrate approach, why she recommends 1.2 to 1.8 grams of protein per kilogram rather than the RDA's 0.8, how to manage medication adjustments for patients at risk of hypoglycemia or hypotension, and how to handle electrolytes, carbohydrate counting, sweeteners, and plant-based variations without losing the patient along the way.Questions Answered in This Episode:• What actually separates a ketogenic diet from a low-carbohydrate diet, and when does the difference matter?• Why is the protein RDA too low for long-term metabolic health, and what range does Spritzler recommend instead?• Who should avoid ketogenic diets entirely, and why are most contraindications manageable with closer supervision?• How should medications be monitored and adjusted when a patient begins carbohydrate restriction?• Should patients count net carbs or total carbs, and why are packaged "net carb" labels unreliable?• Can a ketogenic diet be done as a vegetarian or vegan?A practice-tested blueprint for turning carbohydrate restriction from a prescription into a therapy patients can sustain.Special thanks to the sponsors of this episode:✅ Genova Connect: Get 15% off any Genova Connect test kit with code METABOLICLINK here.✅ iRestore: Get a special discount on the iRestore Illumina Face Mask with code LINK here.✅ fatty15: Get an additional 50% off a 90-day subscription starter kit with code METABOLICLINK.✅ Zocdoc: Find and instantly book a top-rated doctor here.More Links• Franziska's website: lowcarbdietitian.com• The Metabolic Initiative (expert lectures, CME, ad-free episodes, live Q&As; first 7 days free): membership.metabolicinitiative.comIn every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!In every episode of The Metabolic Link, we'll uncover the very latest research on metabolic health and therapy. If you like this episode, please share it, subscribe, follow, and leave us a comment or review on whichever platform you use to tune in!You can find us on all your major podcast players here and full episodes are also up on our Metabolic Health Summit YouTube channel!Find us on social: InstagramFacebookYouTubeLinkedInPlease keep in mind: The Metabolic Link does not provide medical or health advice, but rather general information that does not serve as a substitute for a licensed healthcare professional. Never delay in seeking medical advice from an appropriately licensed medical provider for any health condition that you may have.

They're BACK! After disappearing from the U.S. markets years ago, Single Stock Futures are making a comeback, and this time the CME Group is bringing them back in a big way. But the big question is... Do traders actually need them? In today's episode, we'll break down the revival of Single Stock Futures (SSFs) and explain exactly what these products are, how they work, and why the CME believes the timing is right to bring them back. The new contracts allow traders to gain futures exposure to individual stocks such as Nvidia, Tesla, Microsoft, Alphabet, Meta and dozens of other major U.S. companies—without actually owning the underlying shares. And there are some interesting potential advantages. We'll discuss: What exactly is a Single Stock Future? Why did Single Stock Futures disappear in the first place? Why is the CME bringing them back NOW? How do they compare with simply buying the stock? How do they compare with stock options? What are the margin and leverage implications? Why nearly 24-hour trading could be a major advantage How Single Stock Futures make shorting stocks much easier Who should—and shouldn't—consider trading them? CME has launched 55 full-sized Single Stock Futures and 22 Micro Single Stock Futures, giving traders the ability to control exposure equivalent to either 100 shares or, with the Micros, just 10 shares. That could make these contracts particularly interesting for active traders looking for greater capital efficiency, easier short exposure, and the ability to react to news outside normal stock-market hours. But just because Wall Street creates a new product doesn't mean you need to trade it. The real question isn't whether Single Stock Futures are exciting. It's whether they give you an advantage over the products you already use. That's what we'll figure out on today's show. Learn more about the new contracts:

The owner of the Shops at North Bridge plans a $40 million revamp for the vertical mall. Crain's commercial real estate reporter Rachel Herzog discusses the shopping center, and other Mag Mile news, with host Amy Guth. Plus: Bears eye second Hammond site as Indiana push advances, why Bally's is slowing casino construction in its fight with City Hall, CME seeks 24/7 trading of silver futures in retail push and CEOs pushed White House to delay ultra-processed food definition. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics: Introduction (0:00) The Biopathophysiology of Myelofibrosis (MF) (2:19) Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49) Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00) Upcoming at European Hematology Association (EHA) 2026 (49:22) CME information and select publications

Send us Fan MailWhat if I told you that you could increase your income by thirty thousand... fifty thousand... maybe even eighty thousand dollars a year... without seeing a single additional patient?Would you believe me if I told you the answer isn't working harder, squeezing in one more patient, staying later at the office, or sacrificing another evening with your family?What if I told you the answer is simply documenting the work you're already doing and allowing yourself to be paid appropriately for it?If that sounds too good to be true, stay with me, because today we're talking about one of the biggest financial leaks we see in physician practices across the country. It's not declining reimbursement. It's not staffing shortages. It's not rising overhead. Those are certainly challenges, but there's another issue that quietly costs physicians tens of thousands of dollars every year.It's undercoding.Specifically, physicians who are providing Level 4 care but continue to bill Level 3 visits out of habit, fear, or simply because no one ever taught them differently.If you've ever finished a full day of clinic, felt mentally exhausted, looked at your schedule, and wondered, "How am I working this hard and still feeling like my practice isn't where it should be financially?" then this episode is for you.Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: https://share.hsforms.com/1FMup6xLPSpeA8hB77caYQwd32sx?hsCtaAttrib=171926995377 Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Promo pricing available now: https://education.healtheps.com/offers/Ry3zfLYp/checkout?coupon_code=PHYSEDGE3000 Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/    

In our third Summer School episode this season, hosts Dr. Temara Hajjat and Dr. Jordan Whatley have taken highlights from past episodes on celiac disease and put them into a special episode full of clinical pearls.Former expert guests Dr. Edwin Liu, Dr. Ivor Hill, Dr. Maureen Leonard, Dr. Marissa Stahl, Dr. Arun Singh, and Dr. Justine Turner cover a range of topics from early determinants of celiac disease risk to making a biopsy vs. non biopsy diagnosis.Our Bowel Sounds Summer School series will include four episodes each summer on big topics in our field, artisanally crafted for the ears of learners of all stages from the young student to the seasoned attending.Learning Objectives:Understand the factors influencing developing celiac disease.Review an approach to the evaluation and management of celiac disease.Review the indications and evidence for biopsy vs. non biopsy diagnosis for celiac disease.Send us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics: Introduction (00:00) Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45) Role of Inavolisib in HR-Positive Metastatic Breast Cancer (mBC) (13:00) Strategies to Prevent and Manage Hyperglycemia (27:02) Clinical Utility of Capivasertib for HR-Positive mBC (38:09) Mitigation and Management of Gastrointestinal Adverse Events (51:05) Management of Dermatologic Adverse Events (59:58) Potential Role of Gedatolisib in the Management of HR-Positive mBC (1:08:42) Monitoring and Management of Cytopenias (1:21:23) CME information and select publications

What does academic productivity really mean—and how is it measured? In this episode of the Definitive Guide to Research series, Grace Xiong, MD, and Andrew Schoenfeld, MD, MSc discuss the key metrics used to evaluate academic success, including publication volume, research impact, authorship, mentorship, and scholarly influence. They also share practical strategies for building a balanced research portfolio, increasing the visibility of your work, negotiating academic expectations, and aligning your research efforts with your long-term career goals.This video is part of the “NASS' Definitive Guide to Successful Research: Writing, Reviewing, Publishing” series from NASS. New episodes will be released over the coming months, with select content available on YouTube.Subscribe to NASS Anytime to be the first to access the full course as new sessions are released, including all YouTube content plus exclusive CME education available only through the platform: https://nassanytime.spine.org/

Featuring perspectives from Dr Anne Chiang, Dr Apar Kishor Ganti, Dr Luis Paz-Ares and Dr Misty Dawn Shields, moderated by Dr Shields, including the following topics: Introduction (0:00) Optimizing First-Line and Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (SCLC) — Dr Shields (2:17) Management of Relapsed/Refractory SCLC — Dr Paz-Ares (33:24) Ongoing Investigation and Potential Role of Antibody-Drug Conjugates in SCLC — Dr Chiang (1:02:28) Management of Limited-Stage SCLC — Dr Ganti (1:31:54) CME information and select publications

BEEF: I'm going to start with the weekly beef harvest.  Last week's total was 512K head; the prior week was 528K head.  I don't recall this small a weekly harvest on a non-holiday week.  Packers will continue to try and tighten availability to support pricing.  They are having some success as Ribeyes and tenderloins are moving higher heading to Labor Day.  Overall, though prices are moving lower, we should see some appreciation as we get closer to Labor Day.  Grinds and rounds are moving lower; thin meats are mixed as briskets have new support while flanks and sirloin flap continue to decline.  I think we've got a week, maybe two, before we see this market move higher again.  Stay ahead of your needs; product will be tight, but better values will be available.  POULTRY: Chicken market is back to moving a bit higher.  Up with Boneless skinless random breast and wings.  Tenders still showing some weakness, moving a few pennies lower.  This year's robust chicken production growth is expected to cool off heading into fall, so this market could turn higher, but I'm not seeing anything yet.  On the avian flu report, another week, no new cases, and we will take that win every time.  GRAINS: Grains continue to decline from the surge we saw two weeks ago.  Corn closed at $4.51, down from last week's $4.69; soy at $11.53, down from last week's $11.71, and wheat closed at $6.07, down from last week's $6.30.  We are in the height of the growing season for corn and soy, and we do have some drought in parts of the country to deal with, but that is mostly west of the prime growing areas.  Still looks like another big crop year.  PORK: Pork bellies, they moved higher again this week, today's close $164 up from last week's $159.  I do think we are about at the top of this market, just looking to see when we'll start moving lower.  Right now, I'd buy just what I need.  Pork loins are up a nickel, ribs and butts holding steady.  Once we get past Labor Day, I do expect some declines.  DAIRY: Thursday's CME close saw both barrel and block decline 2 while butter recovers from the recent declines up 6.  We have plenty of raw material for dairy, so I don't expect too much from this recent run. Savalfoods.com | Find us on Social Media: Instagram, Facebook, YouTube, Twitter, LinkedIn

Click the link http://kalshi.com/r/MOSES or download the Kalshi App and use code MOSES to sign up and trade today! Checkout WAWD on Substack: https://whatarewedoingonthedesk.substack.com/OTT On this week's podcast, Danny Moses speaks with Nicole Kagan, head of research at Kalshi, about her path from Bridgewater to Oxford and then to Kalshi to help build the contract-writing and research functions. Kagan explains how Kalshi sources market ideas internally, from partners, and from users, then evaluates whether a contract is objective, economically justified, and resolvable, often reusing pre-certified templates or submitting new rules for CFTC self-certification. She discusses how Kalshi reviews underperforming markets, prioritizes price discovery, and can keep low-volume markets live. They cover Kalshi's prediction markets conference, institutional hedging examples, and Fed research finding Kalshi markets more accurate on inflation and Fed funds, including an FOMC pricing divergence versus CME futures. Moses highlights Kalshi's research links and AI/compute work, then shares his weekly Kalshi picks focused on the Bank of Japan and USD/JPY. -- ABOUT THE SHOW For decades, Danny has seen it all on Wall Street and has built his reputation on integrity, curiosity and skepticism that he will bring with him each week. Having traded through the Great Financial Crisis and being featured in "The Big Short" is only part of the experiences Danny wants to share with the listener. This weekly podcast cuts through market noise, offering entertaining and informative discussions with expert guests giving their views of the financial world and the human side of it. Whether you're a seasoned investor or just getting started, On The Tape provides something for all listeners. Follow Danny on X: @dmoses34 The financial opinions expressed are for information purposes only. The opinions expressed by the hosts and participants are not an attempt to influence specific trading behavior, investments, or strategies. Past performance does not necessarily predict future outcomes. No specific results or profits are assured when relying on this content. Before making any investment or trade, evaluate its suitability for your circumstances and consider consulting your own financial or investment advisor. The financial products discussed in 'On The Tape' carry a high level of risk and may not be appropriate for many investors. If you have uncertainties, it's advisable to seek professional advice. Remember that trading involves a risk to your capital, so only invest money that you can afford to lose. Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service.

Richard Mainwaring, MD, has been a pediatric cardiac surgeon since 1990 and has been a faculty member at the Stanford University School of Medicine since 2003.During Dr. Mainwaring's career as a surgeon, he has contributed to this specialized field of surgery in many realms, including clinical medicine, basic science research, and publications. Dr. Mainwaring is a member of all four professional thoracic surgical organizations, including the American Association of Thoracic Surgery, Society for Thoracic Surgeons, Western Thoracic Surgical Association, and the Southern Thoracic Surgical Association and is also a member of the American College of Surgeons and Congenital Heart Surgeons' Society.In 2012, the congenital cardiac surgery fellowship program at Lucile Packard Children's Hospital (LPCH) received accreditation from the Accreditation Council for Graduate Medical Education. This program is one of 17 accredited congenital cardiac surgery training programs in the US. Dr. Mainwaring has been program director at LPCH since its inception and is currently Chairperson of the Congenital Thoracic Surgical Directors Association. Dr. Mainwaring teaches intra-operative management and surgical technique to the congenital cardiac surgery fellows.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

An 11-year-old boy in rural Zambia once told Dr. Genesis Mwamba that he was about to attend school wearing shoes for the first time in his life. That moment, Dr. Mwamba says, crystallized why he started the Lead Me Back Foundation to provide school supplies and other support to marginalized communities in his native country.   As you'll learn in this inspiring installment in our NextGen Journeys series, Dr. Mwamba started the foundation in 2021while still a medical student because he had experienced the power of education as an “equalizer” in his own life, taking him from humble roots to a career in medicine. He and his colleagues have grown the bootstrapped organization to a point where it now provides hundreds of thousands of people across the country with educational access, climate education and community health clinics. “I've always been drawn to opportunities and initiatives that bring help to humankind,” he tells Raise the Line host Dr. Parsa Mohri. This episode also explores: What building "with" a community rather than "for" it looks like in practice; The storytelling strategy that attracted donors and partners; How his mother's untimely death inspired his commitment to preventive medicine.   Mentioned in this episode: Lead Me Back Foundation If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In today's episode, host Dr. Ben Young is joined by Dr. Stephen McLeod, Academy CEO, and Rebecca Hyder, Vice President of Governmental Affairs. The panel discusses why we have a National Eye Institute (NEI), how it was successfully preserved as an independent, stand-alone entity within the National Institutes of Health (NIH), and what threats to the institute remain on the horizon. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Featuring perspectives from Dr Yelena Y Janjigian, Dr Manish A Shah and Prof Eric Van Cutsem, moderated by Dr Janjigian, including the following topics: Introduction (0:00) HER2-Targeted Approaches in Advanced Gastroesophageal Cancers — Prof Van Cutsem (2:08) Targeting CLDN18.2 in Advanced Gastroesophageal Cancers — Dr Shah (30:54) Available Immunotherapeutic Strategies for Advanced Gastroesophageal Cancers — Dr Janjigian (1:01:39) CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics: Introduction (0:00) Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22) Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24) Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31) Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01) Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24) CME information and select publications

Click the link http://kalshi.com/r/MOSES or download the Kalshi App and use code MOSES to sign up and trade today!Checkout WAWD on Substack: https://whatarewedoingonthedesk.substack.com/OTTOn this week's podcast, Danny Moses speaks with Nicole Kagan, head of research at Kalshi, about her path from Bridgewater to Oxford and then to Kalshi to help build the contract-writing and research functions. Kagan explains how Kalshi sources market ideas internally, from partners, and from users, then evaluates whether a contract is objective, economically justified, and resolvable, often reusing pre-certified templates or submitting new rules for CFTC self-certification. She discusses how Kalshi reviews underperforming markets, prioritizes price discovery, and can keep low-volume markets live. They cover Kalshi's prediction markets conference, institutional hedging examples, and Fed research finding Kalshi markets more accurate on inflation and Fed funds, including an FOMC pricing divergence versus CME futures. Moses highlights Kalshi's research links and AI/compute work, then shares his weekly Kalshi picks focused on the Bank of Japan and USD/JPY.--ABOUT THE SHOWFor decades, Danny has seen it all on Wall Street and has built his reputation on integrity, curiosity and skepticism that he will bring with him each week. Having traded through the Great Financial Crisis and being featured in "The Big Short" is only part of the experiences Danny wants to share with the listener. This weekly podcast cuts through market noise, offering entertaining and informative discussions with expert guests giving their views of the financial world and the human side of it. Whether you're a seasoned investor or just getting started, On The Tape provides something for all listeners.Follow Danny on X: @dmoses34The financial opinions expressed are for information purposes only. The opinions expressed by the hosts and participants are not an attempt to influence specific trading behavior, investments, or strategies. Past performance does not necessarily predict future outcomes. No specific results or profits are assured when relying on this content.Before making any investment or trade, evaluate its suitability for your circumstances and consider consulting your own financial or investment advisor. The financial products discussed in 'On The Tape' carry a high level of risk and may not be appropriate for many investors. If you have uncertainties, it's advisable to seek professional advice. Remember that trading involves a risk to your capital, so only invest money that you can afford to lose.Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service. Hosted on Acast. See acast.com/privacy for more information.

Update Series (2026): Case Based Medical and Surgical Management of Peyronie's Disease Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Matthew Ziegelmann, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

Featuring perspectives from Dr John V Heymach and Dr Maurice Pérol, including the following topics: Introduction: Relative Impact of Targeted Treatment (0:00) HER2 Alterations (8:04) KRAS Mutations (24:25) MET Overexpression (30:34) ALK Fusions (32:34) ROS1 Fusions (42:36) RET Fusions (52:00) CME information and select publications

Send us Fan MailPlanning a medical office construction or renovation is one of the largest investments most physician owners will ever make—but it's also one of the least familiar. The difference between a project that finishes on time and on budget and one that's plagued by delays, change orders, and escalating costs often comes down to one thing: preparation.In this episode of Medical Money Matters, I sit down with my good friend Jim Lampus, co-founder of Norwest Contractors and DesignLab, to discuss why medical construction is an inherently uneven playing field. Physicians may only undertake one or two construction projects during their careers, while contractors manage them every day. Jim shares how healthcare leaders can level the playing field by asking the right questions, choosing the right construction partner, and insisting on thorough planning before the first wall is ever built.We also explore one of the biggest frustrations in medical construction: contractors who submit unrealistically low bids, only to make up the difference through a steady stream of costly change orders once construction begins. Jim explains why comprehensive due diligence, detailed preconstruction planning, and transparent estimating are the keys to avoiding unpleasant surprises and delivering a successful project.Whether you're building a new medical office, expanding your practice, or renovating your existing space, this episode is packed with practical advice that can save you time, money, and unnecessary stress while helping your project stay on schedule and on budget. Jim can be reached at: https://www.norwestgc.com/ or https://www.linkedin.com/in/jim-lampus-62981124/ Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: https://share.hsforms.com/1FMup6xLPSpeA8hB77caYQwd32sx?hsCtaAttrib=171926995377 Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Promo pricing available now: https://education.healtheps.com/offers/Ry3zfLYp/checkout?coupon_code=PHYSEDGE3000 Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/    

Learn more about Astraeus Wealth Management: http://astraeuswealth.com/partner-with-us Guy Adami is joined by Peter Boockvar, CIO of OnePoint BFG Financial, to break down the growing cracks in the Bank of Japan's decades-long rate repression experiment and what a yen reversal could mean for global bond markets. They dig into the historic move in Treasury yields following Kevin Warsh's press conference, rising credit stress in the AI trade (including Meta's off-balance-sheet financing and CoreWeave's blown-out credit default swaps), and why single-stock volatility may be signaling something bigger. They close out with a deep dive on gold — why central banks keep buying even as the metal cools off. Then, Dan Nathan and Guy Adami sit down with Jin Hennig, Managing Director and Global Head of Metals at CME Group, live from CME's New York office. They cover gold's pullback from its 2026 highs, the case for why central bank demand isn't going anywhere, the launch of CME's new 24/7 gold futures product, and what the September Fed meeting could mean for prices. —FOLLOW USYouTube: @RiskReversalMediaInstagram: @riskreversalmediaTwitter: @RiskReversalLinkedIn: RiskReversal MediaThe financial opinions expressed in Risk Reversal content are for information purposes only. The opinions expressed by the hosts and participants are not an attempt to influence specific trading behavior, investments, or strategies. Past performance does not necessarily predict future outcomes. No specific results or profits are assured when relying on Risk Reversal.Before making any investment or trade, evaluate its suitability for your circumstances and consider consulting your own financial or investment advisor. The financial products discussed in Risk Reversal carry a high level of risk and may not be appropriate for many investors. If you have uncertainties, it's advisable to seek professional advice. Remember that trading involves a risk to your capital, so only invest money that you can afford to lose.Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service.

Crypto News: Senate may pass the Clarity Act this coming week as the August 7th deadline approaches but the House is gone so the bill cannot be signed into law till September 2026. XRP Ledger upgrade brings back features once pulled over critical bugs. SEC keeps Nasdaq bitcoin options on hold after granting CME review.

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01) CME information and select publications

Highlights from the PER® CME activity "From Trials to the Clinic ‒ Incorporating New Advances in Metastatic TNBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts William Gradishar, MD, FASCO, FACP; and Kamel Abou Hussein, MD; discuss optimizing first-line treatment selection in metastatic triple-negative breast cancer (TNBC) with emerging antibody-drug conjugates (ADCs) and biomarker-guided strategies.Earn CME credit by completing the full accredited activity (available through July 31, 2027): https://www.gotoper.com/courses/from-trials-to-the-clinic-incorporating-new-advances-in-metastatic-tnbcThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Gilead Sciences, Inc.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00) Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53) Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58) Current and investigational targets of ADCs in gynecologic cancers (17:14) Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56) Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36) Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34) Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05) Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38) CME information and select publications

Apex Fintech Solutions provides the tools and services that enable hundreds of clients to launch, scale, and support digital investing for tens of millions of end investors. The company provides essential infrastructure and a comprehensive ecosystem of cloud-based products to enable and streamline trading, wealth management, cost basis, tax reporting, and, through its subsidiary Apex Clearing™, custody and clearing LEARN MORE: https://apexfintechsolutions.com/?utm_source=Risk+Reversal&utm_medium=Podcast&utm_campaign=701PJ00000fnXhaYAE On today's show, Dan Nathan and Guy Adami break down a wild Thursday in the markets: Microsoft up 15% and Meta down 9% post-earnings, a huge bounce in semis and memory names, and software getting crushed. Guy makes the case that this price action looks more like a topping formation than a bottom. They dig into Fed Chair Kevin Warsh's post-meeting commentary and the bond market selloff it triggered, Bank of Japan intervention on the yen (and what it could mean for volatility), the dollar's potential breakout, Goldman Sachs and Morgan Stanley's pullback from all-time highs, China's AI and chip progress and what it means for KWEB, and where gold goes next after holding the $4,000 level. Plus, Dan sits down with Tim McCourt, Senior Managing Director and Global Head of Equity, FX and Alternative Products at CME Group, to talk about the newly launched Single Stock Futures — how they work, why CME launched them now during earnings season, and how traders can use them alongside stocks, ETFs, and options for risk management. Show Notes AI Lowers Wages But Doesn't Cut Jobs (Apollo) Why the bond market is doubting Fed chairman Warsh (Axios) FactSet Insight (FactSet) —FOLLOW USYouTube: @RiskReversalMediaInstagram: @riskreversalmediaTwitter: @RiskReversalLinkedIn: RiskReversal Media The financial opinions expressed in Risk Reversal content are for information purposes only. The opinions expressed by the hosts and participants are not an attempt to influence specific trading behavior, investments, or strategies. Past performance does not necessarily predict future outcomes. No specific results or profits are assured when relying on Risk Reversal. Before making any investment or trade, evaluate its suitability for your circumstances and consider consulting your own financial or investment advisor. The financial products discussed in Risk Reversal carry a high level of risk and may not be appropriate for many investors. If you have uncertainties, it's advisable to seek professional advice. Remember that trading involves a risk to your capital, so only invest money that you can afford to lose. Derivatives are not suitable for all investors and involve the risk of losing more than the amount originally deposited and any profit you might have made. This communication is not a recommendation or offer to buy, sell or retain any specific investment or service.

Caring for patients using mitragynine-derived substancesFamiliarize yourself with the differences in mitragynine-derived compounds. Understand how to identify and manage kratom use disorder and withdrawal from mitragynine-derived compounds. We're joined by Dr. Jonathan Tanawan (Profile).   Claim CME for this episode at curbsiders.vcuhealth.org!By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education.Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME!Credits Written and Produced, with  Show Notes, Infographic, and Cover Art by Zina Huxley-Reicher, MD  Hosts: Carolyn Chan, MD. MHS and Zina Huxley-Reicher, MD Reviewer: Kento Sonoda, MD, MPH Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest: Jonathan Tanawan, MD Show Segments Intro, disclaimer, guest bio Guest one-liner, Picks of the Week* Case from Kashlak; Definitions Pharmacology of  kratom and other mitragynine-based compounds How to take a mitragynine-specific substance use history Defining a use disorder Withdrawal from kratom  Managing a use disorder with MOUD Legal landscape and regulation  Outro Sponsor: FreedGo to freed.ai and use code FREED50 for fifty dollars off your first month. Sponsor: FigsCurbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.  Sponsor: Continuing Education CompanyVisit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts.